LL-37-derived peptides eradicate multidrug-resistant Staphylococcus aureus from thermally wounded human skin equivalents

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 8, 2014, Pages 4411-4419

  Haisma, Elisabeth M ^a   De Breij, Anna ^a   Chan, Heelam ^a,b   Van Dissel, Jaap T ^a   Drijfhout, Jan W ^a   Hiemstra, Pieter S ^a   El Ghalbzouri, Abdoelwaheb ^a   Nibbering, Peter H ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b PROQR THERAPEUTICS   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; CAP18 LIPOPOLYSACCHARIDE-BINDING PROTEIN; INTERLEUKIN 8; PSEUDOMONIC ACID;

AMINO ACID SEQUENCE; ARTIFICIAL SKIN; BIOFILM; BIOLOGICAL MODEL; BIOSYNTHESIS; BURNS, ELECTRIC; DRUG EFFECTS; EPIDERMIS; EPITHELIUM CELL; FIBROBLAST; GROWTH, DEVELOPMENT AND AGING; HUMAN; METABOLISM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MITOCHONDRION; MOLECULAR GENETICS; PATHOLOGY; SECRETION (PROCESS); SOLID PHASE SYNTHESIS; SYNTHESIS; WOUNDS AND INJURIES;

AMINO ACID SEQUENCE; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; BIOFILMS; BURNS, ELECTRIC; EPIDERMIS; EPITHELIAL CELLS; FIBROBLASTS; HUMANS; INTERLEUKIN-8; METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS; MICROBIAL SENSITIVITY TESTS; MITOCHONDRIA; MODELS, BIOLOGICAL; MOLECULAR SEQUENCE DATA; MUPIROCIN; SKIN, ARTIFICIAL; SOLID-PHASE SYNTHESIS TECHNIQUES; WOUNDS AND INJURIES;

EID: 84905368532     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02554-14     Document Type: Article

References (50)

1. Peck MD. 2011. Epidemiology of burns throughout the world. Part I: distribution and risk factors. Burn. 37:1087-1100. http://dx.doi.org/10.1016/j. burns.2011.06.005.
2. Davis SC, Ricotti C, Cazzaniga A, Welsh E, Eaglstein WH, Mertz PM. 2008. Microscopic and physiologic evidence for biofilm-associated wound colonization in vivo. Wound Repair Regen. 16:23-29. http://dx.doi.org/10.1111/j.1524-475X. 2007.00303.x.
3. Erol S, Altoparlak U, Akcay MN, Celebi F, Parlak M. 2004. Changes of microbial flora and wound colonization in burned patients. Burn. 30:357-361. http://dx.doi.org/10.1016/j.burns.2003.12.013.
4. Kooistra-Smid M, Nieuwenhuis M, van Belkum A, Verbrugh H. 2009. The role of nasal carriage in Staphylococcus aureus burn wound colonization. FEMS Immunol. Med. Microbiol. 57:1-13. http://dx.doi.org/10.1111/j.1574-695X.2009. 00565.x.
5. Church D, Elsayed S, Reid O, Winston B, Lindsay R. 2006. Burn wound infections. Clin. Microbiol. Rev. 19:403-434. http://dx.doi.org/10.1128/CMR.19. 2.403-434.2006.
6. Rode H, Hanslo D, de Wet PM, Millar AJ, Cywes S. 1989. Efficacy of mupirocin in methicillin-resistant Staphylococcus aureus burn wound infection. Antimicrob. Agents Chemother. 33:1358-1361. http://dx.doi.org/10.1128/AAC.33.8. 1358.
7. Sinha R, Agarwal RK, Agarwal M. 1997. Povidone iodine plus neosporin in superficial burns-a continuing study. Burn. 23:626-628. http://dx.doi.org/10. 1016/S0305-4179(97)00069-7.
8. Cookson BD. 1998. The emergence of mupirocin resistance: a challenge to infection control and antibiotic prescribing practice. J. Antimicrob. Chemother. 41:11-18.
9. Hetem DJ, Bonten MJ. 2013. Clinical relevance of mupirocin resistance in Staphylococcus aureus. J. Hosp. Infect. 85:249-256. http://dx.doi.org/10.1016/j. jhin.2013.09.006.
10. Høiby N, Bjarnsholt T, Givskov M, Molin S, Ciofu O. 2010. Antibiotic resistance of bacterial biofilms. Int. J. Antimicrob. Agent. 35:322-332. http://dx.doi.org/10.1016/j.ijantimicag.2009.12.011.
11. Stewart PS, Costerton JW. 2001. Antibiotic resistance of bacteria in biofilms. Lance. 358:135-138. http://dx.doi.org/10.1016/s0140-6736(01)05321-1.
12. Anderl JN, Franklin MJ, Stewart PS. 2000. Role of antibiotic penetration limitation in Klebsiella pneumoniae biofilm resistance to ampicillin and ciprofloxacin. Antimicrob. Agents Chemother. 44:1818-1824. http://dx.doi.org/10. 1128/AAC.44.7.1818-1824.2000.
13. Evans HL, Dellit TH, Chan J, Nathens AB, Maier RV, Cuschieri J. 2010. Effect of chlorhexidine whole-body bathing on hospital-acquired infections among trauma patients. Arch. Surg. 145:240-246. http://dx.doi.org/10.1001/archsurg. 2010.5.
14. Selcuk CT, Durgun M, Ozalp B, Tekin A, Tekin R, Akçay C, Alabalik U. 2012. Comparison of the antibacterial effect of silver sulfadiazine 1%, mupirocin 2%, Acticoat and octenidine dihydrochloride in a fullthickness rat burn model contaminated with multi drug resistant Acinetobacter baumannii. Burn. 38:1204-1209. http://dx.doi.org/10.1016/j.burns.2012.04.009.
15. Heilborn JD, Nilsson MF, Kratz G, Weber G, Sørensen O, Borregaard N, Ståhle-Bäckdahl M. 2003. The cathelicidin anti-microbial peptide LL-37 is involved in re-epithelialization of human skin wounds and is lacking in chronic ulcer epithelium. J. Invest. Dermatol. 120:379-389. http://dx.doi.org/10.1046/j.1523-1747.2003.12069.x.
16. Thakoersing VS, Gooris GS, Mulder A, Rietveld M, El Ghalbzouri A, Bouwstra JA. 2012. Unraveling barrier properties of three different inhouse human skin equivalents. Tissue Eng. Part C Method. 18:1-11. http://dx.doi.org/ 10.1089/ten.TEC.2011.0175.
17. Dai T, Huang YY, Sharma SK, Hashmi JT, Kurup DB, Hamblin MR. 2010. Topical antimicrobials for burn wound infections. Recent Pat. Antiinfect. Drug Discov. 5:124-151. http://dx.doi.org/10.2174/157489110791233522.
18. Zasloff M. 2002. Antimicrobial peptides of multicellular organisms. Natur. 415:389-395. http://dx.doi.org/10.1038/415389a.
19. Nizet V, Ohtake T, Lauth X, Trowbridge J, Rudisill J, Dorschner RA, Pestonjamasp V, Piraino J, Huttner K, Gallo RL. 2001. Innate antimicrobial peptide protects the skin from invasive bacterial infection. Natur. 414:454-457. http://dx.doi.org/10.1038/35106587.
20. Dean SN, Bishop BM, van Hoek ML. 2011. Natural and synthetic cathelicidin peptides with anti-microbial and anti-biofilm activity against Staphylococcus aureus. BMC Microbiol. 11:114. http://dx.doi.org/10.1186/1471-2180-11-114.
21. Zaiou M, Nizet V, Gallo RL. 2003. Antimicrobial and protease inhibitory functions of the human cathelicidin (hCAP18/LL-37) prosequence. J. Invest. Dermatol. 120:810-816. http://dx.doi.org/10.1046/j.1523-1747.2003.12132.x.
22. Overhage J, Campisano A, Bains M, Torfs EC, Rehm BH, Hancock RE. 2008. Human host defense peptide LL-37 prevents bacterial biofilm formation. Infect. Immun. 76:4176-4182. http://dx.doi.org/10.1128/IAI.00318-08.
23. Travis SM, Anderson NN, Forsyth WR, Espiritu C, Conway BD, Greenberg EP, McCray PB, Jr, Lehrer RI, Welsh MJ, Tack BF. 2000. Bactericidal activity of mammalian cathelicidin-derived peptides. Infect. Immun. 68:2748-2755. http://dx.doi.org/10.1128/IAI.68.5.2748-2755.2000.
24. Larrick JW, Hirata M, Balint RF, Lee J, Zhong J, Wright SC. 1995. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect. Immun. 63:1291-1297.
25. Tokumaru S, Sayama K, Shirakata Y, Komatsuzawa H, Ouhara K, Hanakawa Y, Yahata Y, Dai X, Tohyama M, Nagai H, Yang L, Higashiyama S, Yoshimura A, Sugai M, Hashimoto K. 2005. Induction of keratinocyte migration via transactivation of the epidermal growth factor receptor by the antimicrobial peptide LL-37. J. Immunol. 175:4662-4668. http://dx.doi.org/10.4049/jimmunol.175.7.4662.
26. Nell MJ, Tjabringa GS, Wafelman AR, Verrijk R, Hiemstra PS, Drijfhout JW, Grote JJ. 2006. Development of novel LL-37 derived antimicrobial peptides with LPS and LTA neutralizing and antimicrobial activities for therapeutic application. Peptide. 27:649-660. http://dx.doi.org/10.1016/j.peptides.2005.09. 016.
27. Peek FAW, Nell MJ, Brand R, Jansen-Werkhoven TM, van Hoogdalem EJ, Frijns JHM. 2009. Double-blind placebo-controlled study of the novel peptide drug P60.4AC in chronic middle ear infection, presentation L1-337. 49th Intersci. Conf. Antimicrob. Agents Chemother., San Francisco, CA, 12 to 15 September 2009.
28. Fox JL. 2013. Antimicrobial peptides stage a comeback. Nat. Biotechnol. 31:379-382. http://dx.doi.org/10.1038/nbt.2572.
29. Duplantier AJ, van Hoek ML. 2013. The human cathelicidin antimicrobial peptide LL-37 as a potential treatment for polymicrobial infected wounds. Front. Immunol. 4:143. http://dx.doi.org/10.3389/fimmu.2013.00143.
30. Haisma EM, Rietveld M, de Breij A, van Dissel JT, El Ghalbzouri A, Nibbering PH. 2013. Inflammatory and antimicrobial responses to methicillin-resistant Staphylococcus aureus in an in vitro wound infection model. PLoS On. 8:e82800. http://dx.doi.org/10.1371/journal.pone.0082800.
31. El Ghalbzouri A, Hensbergen P, Gibbs S, Kempenaar J, van der Schors R, Ponec M. 2004. Fibroblasts facilitate re-epithelialization in wounded human skin equivalents. Lab. Invest. 84:102-112. http://dx.doi.org/10.1038/labinvest. 3700014.
32. Holland DB, Bojar RA, Farrar MD, Holland KT. 2009. Differential innate immune responses of a living skin equivalent model colonized by Staphylococcus epidermidis or Staphylococcus aureus. FEMS Microbiol. Lett. 290:149-155. http://dx.doi.org/10.1111/j.1574-6968.2008.01402.x.
33. Holland DB, Bojar RA, Jeremy AH, Ingham E, Holland KT. 2008. Microbial colonization of an in vitro model of a tissue engineered human skin equivalent-a novel approach. FEMS Microbiol. Lett. 279:110-115. http://dx.doi.org/10.1111/j. 1574-6968.2007.01021.x.
34. Croes S, Deurenberg RH, Boumans ML, Beisser PS, Neef C, Stobberingh EE. 2009. Staphylococcus aureus biofilm formation at the physiologic glucose concentration depends on the S. aureus lineage. BMC Microbiol. 9:229. http://dx.doi.org/10.1186/1471-2180-9-229.
35. Enright MC, Day NP, Davies CE, Peacock SJ, Spratt BG. 2000. Multilocus sequence typing for characterization of methicillin-resistant and methicillin-susceptible clones of Staphylococcus aureus. J. Clin. Microbiol. 38:1008-1015.
36. de la Fuente-Nuñez C, Korolik V, Bains M, Nguyen U, Breidenstein EB, Horsman S, Lewenza S, Burrows L, Hancock RE. 2012. Inhibition of bacterial biofilm formation and swarming motility by a small synthetic cationic peptide. Antimicrob. Agents Chemother. 56:2696-2704. http://dx.doi.org/10.1128/AAC.00064- 12.
37. el-Ghalbzouri A, Gibbs S, Lamme E, Van Blitterswijk CA, Ponec M. 2002. Effect of fibroblasts on epidermal regeneration. Br. J. Dermatol. 147:230-243. http://dx.doi.org/10.1046/j.1365-2133.2002.04871.x.
38. Ponec M, Weerheim A, Kempenaar J, Mulder A, Gooris GS, Bouwstra J, Mommaas AM. 1997. The formation of competent barrier lipids in reconstructed human epidermis requires the presence of vitamin C. J. Invest. Dermatol. 109:348-355. http://dx.doi.org/10.1111/1523-1747.ep12336024.
39. El Ghalbzouri A, Siamari R, Willemze R, Ponec M. 2008. Leiden reconstructed human epidermal model as a tool for the evaluation of the skin corrosion and irritation potential according to the ECVAM guidelines. Toxicol. In Vitr. 22:1311-1320. http://dx.doi.org/10.1016/j.tiv.2008.03.012.
40. van Rijen M, Bonten M, Wenzel R, Kluytmans J. 2008. Mupirocin ointment for preventing Staphylococcus aureus infections in nasal carriers. Cochrane Database Syst. Rev. (4): CD006216. http://dx.doi.org/10.1002/14651858.CD006216. pub2.
41. Kahlenberg JM, Kaplan MJ. 2013. Little peptide, big effects: the role of LL-37 in inflammation and autoimmune disease. J. Immunol. 191:4895-4901. http://dx.doi.org/10.4049/jimmunol.1302005.
42. Zanetti M, Gennaro R, Romeo D. 1995. Cathelicidins: a novel protein family with a common proregion and a variable C-terminal antimicrobial domain. FEBS Lett. 374:1-5.
43. Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE. 2005. Impact of LL-37 on anti-infective immunity. J. Leukoc. Biol. 77:451-459. http://dx.doi.org/10.1189/jlb.0704380.
44. Flemming K, Klingenberg C, Cavanagh JP, Sletteng M, Stensen W, Svendsen JS, Flaegstad T. 2009. High in vitro antimicrobial activity of synthetic antimicrobial peptidomimetics against staphylococcal biofilms. J. Antimicrob. Chemother. 63:136-145. http://dx.doi.org/10.1093/jac/dkn464.
45. Haisma EM, Rietveld MH, de Breij A, van Dissel JT, El Ghalbzouri A, Nibbering PH. 2013. Inflammatory and antimicrobial responses to methicillinresistant Staphylococcus aureus in an in vitro wound infection model. PLoS On. 8:e82800. http://dx.doi.org/10.1371/journal.pone.0082800.
46. Svenson J, Brandsdal BO, Stensen W, Svendsen JS. 2007. Albumin binding of short cationic antimicrobial micropeptides and its influence on the in vitro bactericidal effect. J. Med. Chem. 50:3334-3339. http://dx.doi.org/10.1021/ jm0703542.
47. Steinstraesser L, Koehler T, Jacobsen F, Daigeler A, Goertz O, Langer S, Kesting M, Steinau H, Eriksson E, Hirsch T. 2008. Host defense peptides in wound healing. Mol. Med. 14:528-537. http://dx.doi.org/10.2119/2008-00002. Steinstraesser.
48. Steinstraesser L, Hirsch T, Schulte M, Kueckelhaus M, Jacobsen F, Mersch EA, Stricker I, Afacan N, Jenssen H, Hancock RE, Kindrachuk J. 2012. Innate defense regulator peptide 1018 in wound healing and wound infection. PLoS On. 7:e39373. http://dx.doi.org/10.1371/journal.pone.0039373.
49. Chow LN, Choi KY, Piyadasa H, Bossert M, Uzonna J, Klonisch T, Mookherjee N. 2014. Human cathelicidin LL-37-derived peptide IG-19 confers protection in a murine model of collagen-induced arthritis. Mol. Immunol. 57:86-92. http://dx.doi.org/10.1016/j.molimm.2013.08.011.
50. Mataraci E, Dosler S. 2012. In vitro activities of antibiotics and antimicrobial cationic peptides alone and in combination against methicillinresistant Staphylococcus aureus biofilms. Antimicrob. Agents Chemother. 56:6366-6371. http://dx.doi.org/10.1128/AAC.01180-12.